Clinical solutions play a vital role in post-market surveillance of medicine. These solutions help to identify, evaluate, and mitigate potential risks associated with a medicine after it has been approved and made available to the public.

One example of a clinical solution is the use of real-world data (RWD) and real-world evidence (RWE) to identify safety and effectiveness issues in a medicine. RWD and RWE are gathered from patients, healthcare providers, and electronic health records and can help to identify patterns and trends that may not have been apparent during clinical trials.

Another clinical solution is the use of pharmacovigilance, which involves the ongoing monitoring of a medicine’s safety and effectiveness. This can include the use of adverse event reporting systems, where healthcare providers and patients can report any potential side effects or problems with a medicine.

Other solutions can include conducting additional clinical trials or observational studies to further evaluate the safety and effectiveness of a medicine, or implementing risk management plans to mitigate any identified risks.

In addition to helping to identify potential safety concerns, clinical solutions can also help to improve the overall effectiveness of a medicine. For example, by using RWD and RWE, it is possible to identify subgroups of patients that may respond particularly well to a medicine, or to identify new uses for a medicine.

Overall, clinical solutions are essential for post-market surveillance of medicine, helping to ensure the safe and effective use of medicine and protecting public health.